摘要
目的:探讨CD4+CD25+调节性T细胞在哮喘发病机制中的作用,为哮喘的临床治疗提供新的思路和方法。方法:分离哮喘患者和正常人外周血单个核细胞(PBMC),用流式细胞仪分析CD4+CD25+调节性T细胞在外周血单个核细胞中的比例;酶联免疫吸附法(ELASA)检测外周血PBMC培养上清IL-4的分泌状况。结果:哮喘组外周血CD4+CD25+调节性T细胞的百分率为(3.2±1.5)%,健康对照组为(6.5±2.5)%,哮喘组明显低于对照组(P<0.05);哮喘组外周血PBMC培养上清IL-4分泌水平为(57.3±13.5)ng/L,健康对照组为(28.6±7.2)ng/L,哮喘组明显高于对照组(P<0.05)。结论:CD4+CD25+调节性T细胞可能参与了哮喘的发生与发展。
Objective：To investigate the role of CD4^＋CD25^＋ regulatory T cells in the pathogenesis of asthma for the purpose of giving new approach of treatment. Methods ：The monouclear cells were isolated from peripheral blood of asthmatic patients and control subjects,and the percentagn of CD4^＋CD25^＋ regulatory T cells was detemined by flow cytometry. The concentrations of IL-4 in PBMC supernatants were measured with enzyme linked immunosorbent assay （ELISA） method. Results：The percentage of CD4^＋CD25^＋ regulatory T cells in PBMC has significantly difference between control group （6.5± 2.5） % and asthmatic patients （3.2 ± 1.5） % （P〈 0. 05）. The concentrations of IL- 4 in PBMC supernatants has significantly difference between control group （28.6±7.2） ng/L and asthmatic patients （57.3±13.5） ng/L（P〈0.05）. Conclusion：The CD4^＋CD25^＋ regulatory T cells involved in the pathogenesis of asthma in human.
出处
《临床医药实践》
2008年第7期485-487,共3页
Proceeding of Clinical Medicine
